These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 27881095)

  • 41. Brain Atrophy as an Outcome of Disease-Modifying Therapy for Remitting-Relapsing Multiple Sclerosis.
    Chylińska M; Komendziński J; Wyszomirski A; Karaszewski B
    Mult Scler Int; 2023; 2023():4130557. PubMed ID: 37693228
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis.
    van den Elskamp IJ; Boden B; Dattola V; Knol DL; Filippi M; Kappos L; Fazekas F; Wagner K; Pohl C; Sandbrink R; Polman CH; Uitdehaag BM; Barkhof F
    Neuroradiology; 2010 Oct; 52(10):875-81. PubMed ID: 20049424
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis.
    De Stefano N; Silva DG; Barnett MH
    CNS Drugs; 2017 Apr; 31(4):289-305. PubMed ID: 28247239
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis.
    Lee H; Nakamura K; Narayanan S; Brown RA; Nash RA; Griffith LM; Steinmiller KC; Devine SM; Hutton GJ; Popat U; Racke MK; Georges GE; Bowen JD; Arnold DL
    Mult Scler Relat Disord; 2021 Sep; 54():103149. PubMed ID: 34284316
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.
    Wattjes MP; Rovira À; Miller D; Yousry TA; Sormani MP; de Stefano MP; Tintoré M; Auger C; Tur C; Filippi M; Rocca MA; Fazekas F; Kappos L; Polman C; Frederik Barkhof ; Xavier Montalban ;
    Nat Rev Neurol; 2015 Oct; 11(10):597-606. PubMed ID: 26369511
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bicaudate ratio as a magnetic resonance imaging marker of brain atrophy in multiple sclerosis.
    Bermel RA; Bakshi R; Tjoa C; Puli SR; Jacobs L
    Arch Neurol; 2002 Feb; 59(2):275-80. PubMed ID: 11843699
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis.
    Bross M; Hackett M; Bernitsas E
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560364
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Cognitive impairment in multiple sclerosis].
    Ochi H
    Brain Nerve; 2014 Oct; 66(10):1201-9. PubMed ID: 25296874
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Within-patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL.
    Opfer R; Ostwaldt AC; Walker-Egger C; Manogaran P; Sormani MP; De Stefano N; Schippling S
    J Neurol; 2018 May; 265(5):1158-1165. PubMed ID: 29549466
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Functional and structural brain MRI changes associated with cognitive worsening in multiple sclerosis: a 3-year longitudinal study.
    Azzimonti M; Preziosa P; Pagani E; Valsasina P; Tedone N; Vizzino C; Rocca MA; Filippi M
    J Neurol; 2023 Sep; 270(9):4296-4308. PubMed ID: 37202603
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cognitive reserve moderates the impact of subcortical gray matter atrophy on neuropsychological status in multiple sclerosis.
    Modica CM; Bergsland N; Dwyer MG; Ramasamy DP; Carl E; Zivadinov R; Benedict RH
    Mult Scler; 2016 Jan; 22(1):36-42. PubMed ID: 25921038
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Measuring brain atrophy in multiple sclerosis.
    De Stefano N; Battaglini M; Smith SM
    J Neuroimaging; 2007 Apr; 17 Suppl 1():10S-15S. PubMed ID: 17425728
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The sequence of structural, functional and cognitive changes in multiple sclerosis.
    Dekker I; Schoonheim MM; Venkatraghavan V; Eijlers AJC; Brouwer I; Bron EE; Klein S; Wattjes MP; Wink AM; Geurts JJG; Uitdehaag BMJ; Oxtoby NP; Alexander DC; Vrenken H; Killestein J; Barkhof F; Wottschel V
    Neuroimage Clin; 2021; 29():102550. PubMed ID: 33418173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study.
    Granberg T; Martola J; Bergendal G; Shams S; Damangir S; Aspelin P; Fredrikson S; Kristoffersen-Wiberg M
    Mult Scler; 2015 Aug; 21(9):1151-8. PubMed ID: 25480866
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Active cognitive reserve influences the regional atrophy to cognition link in multiple sclerosis.
    Booth AJ; Rodgers JD; Schwartz CE; Quaranto BR; Weinstock-Guttman B; Zivadinov R; Benedict RH
    J Int Neuropsychol Soc; 2013 Nov; 19(10):1128-33. PubMed ID: 24050681
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The impact of deep grey matter volume on cognition in multiple sclerosis.
    Lorefice L; Carta E; Frau J; Contu F; Casaglia E; Coghe G; Barracciu MA; Cocco E; Fenu G
    Mult Scler Relat Disord; 2020 Oct; 45():102351. PubMed ID: 32731200
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis.
    Mariottini A; Filippini S; Innocenti C; Forci B; Mechi C; Barilaro A; Fani A; Carlucci G; Saccardi R; Massacesi L; Repice AM
    Mult Scler; 2021 Jan; 27(1):61-70. PubMed ID: 32008439
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis.
    Lazeron RH; Boringa JB; Schouten M; Uitdehaag BM; Bergers E; Lindeboom J; Eikelenboom MI; Scheltens PH; Barkhof F; Polman CH
    Mult Scler; 2005 Oct; 11(5):524-31. PubMed ID: 16193889
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy.
    Stevenson VL; Smith SM; Matthews PM; Miller DH; Thompson AJ
    J Neurol; 2002 Feb; 249(2):171-7. PubMed ID: 11985382
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates.
    Rekik A; Aissi M; Rekik I; Mhiri M; Frih MA
    Brain Behav; 2022 May; 12(5):e2573. PubMed ID: 35398999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.